Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.
Aurora Spine Corporation (ASAPF) delivers innovative spinal implant technologies focused on minimally invasive surgical solutions and regenerative approaches. This news hub provides investors and healthcare professionals with essential updates on the company’s financial developments, product milestones, and clinical advancements.
Access timely announcements including quarterly earnings reports, regulatory approvals for new devices, and strategic partnerships within the medical device sector. Our curated collection ensures transparent tracking of Aurora Spine’s progress in improving spinal care through screwless implant systems and biointegrated solutions.
Discover press releases covering FDA clearances, research collaborations, and executive leadership changes that shape the company’s trajectory. All content is verified for accuracy and relevance to support informed decision-making about ASAPF’s market position and technological contributions.
Bookmark this page for streamlined access to Aurora Spine’s latest developments in spinal healthcare innovation. Check regularly for updates on patent filings, clinical trial results, and industry recognition of their patient-focused medical devices.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced it will release its fourth quarter and fiscal year 2024 financial results on Monday, April 28, 2025, after market hours. The company will host a conference call for investors on Tuesday, April 29, 2025, at 11:00 am ET/8:00am PT.
The company also disclosed a clarification regarding its stock option plan, noting that previous management information circulars for 2023 and 2024 shareholder meetings referenced an outdated version. The correct version, approved by the board in 2022, will be included in the upcoming annual general meeting materials.
Aurora Spine (OTCQB: ASAPF) announced that James Snow, a board member since 2012, has resigned from the Board of Directors to become the company's Regulatory Affairs and Quality Assurance Manager. Snow, who brings over 20 years of medical device experience in regulatory affairs and quality, will focus on ensuring compliance requirements are met and exceeded.
The transition marks Snow's shift from a strategic to an operational role, where he will leverage his industry expertise to drive quality and compliance across Aurora's expanding innovative product portfolio. The company, which specializes in designing and manufacturing innovative medical devices for spinal surgery outcomes, views this internal movement as strengthening their operational capabilities.
Aurora Spine (OTCQB: ASAPF) announced the publication of a biomechanical study in Neurospine journal, demonstrating the superior performance of their SiLO TFX™ MIS Sacroiliac Joint Fixation System compared to traditional techniques.
The study revealed that the posterior interposition technique used by SiLO TFX™ achieved a 42% ± 8% reduction in joint motion, significantly outperforming the 14% ± 4% reduction observed with conventional posterolateral transosseous techniques. The system maintained stable bone-implant interface across all specimens, while traditional methods showed migration in 20%-50% of cases.
Key advantages of the SiLO TFX™ system include:
- Less bone volume removal
- Larger surface area for fusion
- Enhanced stability through transfixing design
- Minimally invasive approach
Aurora Spine (OTCQB: ASAPF) has received FDA 510(k) clearance for its new AERO™ Facet Fusion System, a minimally invasive solution for facet joint-related pain and instability. The patent-pending device is cleared for spinal levels C2 to S1 and can be used as a standalone procedure or alongside larger spinal fusion surgeries.
The system is specifically designed for patients with mechanical back pain, minor instability, or degenerative joint disease who haven't responded to conservative therapies. Initial surgeries with AERO are scheduled to begin in late Q3 2025, accompanied by a clinical study to validate outcomes and long-term benefits.
The AERO system features intuitive instrumentation and implant technology aimed at promoting bone fusion while minimizing soft tissue disruption, aligning with the company's focus on patient-first, surgeon-friendly innovations.
Aurora Spine (OTCQB: ASAPF) has announced its participation in the 2025 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting from March 10-14, 2025, at the San Diego Convention Center – Booth #1847.
At the world's largest gathering of orthopedic professionals, Aurora Spine will showcase its innovative product line, including:
- DEXA-C™: A cervical cage for ACDF procedures featuring patented DEXA Technology™ that matches implant density to patient's bone density
- SiLO TFX™ SI Fusion System: A patented, minimally invasive system for sacroiliac joint fusion, designed to treat conditions like sacroiliac joint disruptions and degenerative sacroiliitis
- ZIP product line: Offering Screwless Procedure for MIS Interspinous fusion
CEO Trent Northcutt emphasized the meeting's importance for introducing doctors to new technologies, particularly highlighting DEXA-C's unique bone density matching capability.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced the completion of patient enrollment in its groundbreaking REFINE study, evaluating the ZIP™ Interspinous Fixation device for back pain treatment. This first-of-its-kind prospective, multi-center, multi-specialty clinical trial aims to assess the safety and efficacy of lumbar interlaminar fusion devices.
The study results will be published with one-year data, followed by a two-year cohort publication, and will be presented at the American Society of Pain and Neuroscience (ASPN) annual conference in July 2025. The REFINE study uniquely combines expertise from neurosurgeons, orthopedic surgeons, and interventional pain physicians to evaluate the ZIP™ MIS Interspinous Fusion System, offering a minimally invasive alternative to traditional spinal surgery for patients with lumbar spinal stenosis and degenerative disc disease.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced key leadership promotions, elevating Matt Paxton to Executive Vice President of Sales and Katelyn Sims to Area Vice President of Commercialization and Key Accounts.
As Executive Vice President of Sales, Paxton will lead company-wide initiatives focusing on operational excellence and strategic growth. Sims, in her new role as Area Vice President of Commercialization and Key Accounts, will oversee sales and market strategies implementation to expand the reach of Aurora Spine's products.
Matthew Goldstone, Chief Commercialization Officer, emphasized that these promotions align with Aurora Spine's 2025 goals and reflect the company's commitment to developing internal talent. The company, which designs and manufactures innovative medical devices for spinal surgery, aims to continue its focus on simplifying complex spinal procedures and delivering superior patient outcomes.
Aurora Spine (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices for spinal surgery, has announced a conference call to discuss its third quarter fiscal 2024 financial results for the period ended September 30, 2024. The conference call is scheduled for Monday, October 28, 2024, at 11:00 a.m. Eastern Time. Investors can join via phone or webcast, with replay options available until November 4, 2024.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has launched its new OSTEO ONYX™ lumbar fusion system, featuring Rough Surface Technology (RST). This innovative system is designed to accommodate both standard spine patients and those with challenging conditions such as osteopenia or osteoporosis.
Ron Eckels, US Director of Spine at Aurora Spine, highlighted the system's versatility in treating a wide range of patients. Dr. Daniel Barba of San Diego, CA, was the first surgeon to use the Hydra Osteo Onyx MIS System in the United States. He praised the roughened surface technology for providing excellent purchase within the pedicle, benefiting patients with osteoporosis or poor bone quality. Dr. Barba also noted that the range of MIS screws (4.5mm to 10.5mm) allows for minimally invasive procedures, leading to improved patient recovery and satisfaction.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced its participation in the 2024 North American Spine Society (NASS) Annual Meeting from September 25-28, 2024, at McCormick Place, Chicago. The company will showcase its latest innovations at Booth #4510, including:
- SiLO™ TFX SI Fusion System for sacroiliac joint fusion surgery
- DEXA-C cervical interbody cage system with patented DEXA™ Technology
- Hydra™ and OSTEO-ONYX™ lumbar fusion systems with Rough Surface Technology (RST)
- ZIP-51® Interlaminar Fusion System for minimally invasive L5/S1 fusion
Aurora Spine's executives emphasize the transformative nature of their products, particularly highlighting the DEXA-C implant line as the world's first patient-matched interbody implant system.
